Sameh Shaheen¹, Ahmed S. H. Elserafy¹, Mohamed Amin², Ramy Hassan², Emad R. Issak^3*

Show more
¹ Cardiology Department, Ain Shams University, Cairo, Egypt.
² AstraZeneca, Cairo, Egypt.
³ ClinAmygate, Cairo, Egypt.
Show less

Abstract: Background: Serum level of cholesterol is one of the most vital risk factors for cardiovascular diseases (CVD). Statins are highly effective drugs for reducing serum cholesterol; hence, preventing coronary heart disease (CHD). Rosuvastatin (Crestor) is one of the most potent and widely prescribed statins. Even though generic statins have been approved based on their bioequivalence with brand-name drugs, there remains considerable concern as regards their effectiveness and safety. Most clinicians and patients welcome the generic drug decreased costs; however, it is indispensable for them that effectiveness and safety are not compromised. Thus, the rationale intended for this study is to compare brand rosuvastatin and generic rosuvastatin as regard their economic impact using a cost-minimization analysis. Methods: This cost-minimization model estimates potential impact of rosuvastatin brand versus generic on the healthcare resource utilization for one-year frame from the payer perspective. The model conforms to real practice of management of hyperlipidemia in Egypt and was validated by experts. Results: The drug costs in the rosuvastatin brand group were 3,155,250 EGP while in the generic group were 2,299,030 EGP. The costs of CVD events in the rosuvastatin brand group were 5,863,558 EGP, while in the generic group were 6,810,180 EGP. The total costs in the rosuvastatin brand group were 9,018,808 EGP, while in the generic group were 9,109,210 EGP with a difference of −100,047 EGP. Conclusions: In conclusion, the real cost of generic treatment is more than that of the brand statin when taking into consideration the cardiovascular events.

Keywords: Rosuvastatin, Generics, Cardiovascular Events, Cost-Minimization

Cite this paper: Shaheen, S. , Elserafy, A. , Amin, M. , Hassan, R. and Issak, E. (2019) Brand versus Generic Rosuvastatin in Egyptian Patients with Hyperlipidemia; Cost-Minimization Analysis. International Journal of Clinical Medicine, 10, 631-638. doi: 10.4236/ijcm.2019.1012052.

References

[1]   Law, M.R., Wald, N.J. and Rudnicka, A.R. (2003) Quantifying Effect of Statins on Low Density Lipoprotein Cholesterol, Ischaemic Heart Disease, and Stroke: Systemic Review and Meta-Analysis. BMJ, 326, 1423.
https://doi.org/10.1136/bmj.326.7404.1423

[2]   Zodda, D., Giammona, R. and Schifilliti, S. (2018). Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy (Basel, Switzerland), 6, 10.
https://doi.org/10.3390/pharmacy6010010

[3]   Davidson, M., Ma, P., Stein, E.A., Gotto, A.M., Raza, A., Chitra, R. and Hutchinson, H. (2002) Comparison of Effects on Low-Density Lipoprotein Cholesterol and High-Density Lipoprotein Cholesterol with Rosuvastatin versus Atorvastatin in Patients with Type IIa or IIb Hypercholesterolemia. American Journal of Cardiology, 89, 268-275.
https://doi.org/10.1016/S0002-9149(01)02226-3

[4]   Paoletti, R., Fahmy, M., Mahla, G., Mizan, J. and Southworth, H. (2001) Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind Study. Cardiovascular Risk, 8, 383-390.
https://doi.org/10.1177/174182670100800608

[5]   Adams, S.P., Sekhon, S.S. and Wright, J.M. (2014) Lipid-Lowering Efficacy of Rosuvastatin. Cochrane Database of Systematic Reviews, No. 11, CD010254.

[6]   Canadian Agency for Drugs and Technologies in Health (2015) Similarities and Differences between Brand Name and Generic Drugs.
https://www.cadth.ca/sites/default/files/pdf/simi
larities_differences_brandname_generic_drugs_e.pdf

[7]   Gallelli, L., Palleria, C., De Vuono, A., Mumoli, L., Vasapollo, P., Piro, B. and Russo, E. (2013) Safety and Efficacy of Generic Drugs with Respect to Brand Formulation. Journal of Pharmacology & Pharmacotherapeutics, 4, 110-114.
https://doi.org/10.4103/0976-500X.120972

[8]   Iosifescu, A., Halm, E.A., McGinn, T., Siu, A.L. and Federman, A.D. (2008) Beliefs about Generic Drugs among Elderly Adults in Hospital-Based Primary Care Practices. Patient Education and Counseling, 73, 377-383.
https://doi.org/10.1016/j.pec.2008.07.012

[9]   Lopez, V.A., Franklin, S.S., Tang, S. and Wong, N.D. (2007) Coronary Heart Disease Events Preventable by Control of Blood Pressure and Lipids in US Adults with Hypertension. The Journal of Clinical Hypertension (Greenwich), 9, 436-443.
https://doi.org/10.1111/j.1524-6175.2007.06518.x

[10]   Bart, B.Y., Luchinkina, E.E., Gordeev, I.G., Arutyunov, G.P. and Taratukhin, E.O. (2016) On Behalf of the Workgroup of Paritet Trial. Comparative Analysis of the Efficacy and Safety of Rosuvastatin and Original Rosuvastatin. Kardiologiia, 56, 46-49.
https://doi.org/10.18565/cardio.2016.6.46-49

[11]   Abd-Elaziz, K.M., Gabal, M.S., Aldafrawy, O.A., Abou-Seif, H.A.-A. and Allam, M.F. (2014) Prevalence of Metabolic Syndrome and Cardiovascular Risk Factors among Voluntary Screened Middle-Aged and Elderly Egyptians. Journal of Public Health, 37, 612-617.
https://doi.org/10.1093/pubmed/fdu097

[12]   Abd-Allah, F., Khedr, E., Oraby, M.I., Bedair, A.S., Georgy, S.S. and Moustafa, R.R. (2017) Stroke Burden in Egypt: Data from Five Epidemiological Studies. International Journal of Neuroscience, 1-7.

[13]   Almahmeed, W., Arnaout, M.S., Chettaoui, R., Ibrahim, M., Kurdi, M.I., Taher, M.W. and Mancia, G. (2012) Coronary Artery Disease in Africa and the Middle East. Therapeutics and Clinical Risk Management, 8, 65-72.
https://doi.org/10.2147/TCRM.S26414

[14]   Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J. and Loder, E. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health, 16, 231-250.
https://doi.org/10.1016/j.jval.2013.02.002

[15]   Rascati, K.L. (2014) Essentials of Pharmacoeconomics. 2nd Edition, Lippincott Williams & Wilkins, Philadelphia.

[16]   Arenas-Guzman, R., Tosti, A., Hay, R. and Haneke, E. (2005) National Institute for Clinical Excellence. Pharmacoeconomics: An Aid to Better Decision-Making. The Journal of the European Academy of Dermatology and Venereology, 19, 34-39.
https://doi.org/10.1111/j.1468-3083.2005.01285.x

[17]   Ambrosioni, E. and Borghi, C. (2014) Pharmacoeconomic and Cost-Benefit Aspects. In: Manual of Hypertension of the European Society of Hypertension, CRC Press, Boca Raton, 316-320.
https://doi.org/10.1201/b17072-51